Venlafaxine Hydrochloride
Product Images NDC 58118-0097

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Venlafaxine Hydrochloride (NDC 58118-0097). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Clinical Solutions Wholesale, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

00093738456

FDA Label Image

00093738556

FDA Label Image

00093738656

FDA Label Image

Figure 1: Effect Of Interacting Drugs On The Pharmacokinetics Of Venlafaxine And Active Metaboilte O-desmethylvenlafaxine (odv). (Image 01)

This appears to be a table showing the interaction between various drugs and their effect on the pharmacokinetics of Venlafaxine in individuals who are extensive metabolizers (EMs) or poor metabolizers (PMs) of the CYP2D6 enzyme. The table includes recommendations on dosages and precautions to be taken when prescribing Venlafaxine in combination with the listed drugs. However, the text is not very clear and contains many errors, making it difficult to fully understand.*

FDA Label Image

Figure 2: Effect Of Venlafaxine On The Pharmacokinetics Interacting Drugs And Their Active Metabolites. (Image 02)

This is a table of drugs and their interacting analytes. It provides recommendations on whether to avoid concomitant use, adjust the dose or monitor blood pressure based on the fold change and 90° R&dommendation. The table includes drugs such as Ethanol, Diazepam, Alprazolam, Indinavir, Metoprolol, Risperidone, Imipramine, Haloperidol, Caffeine, Tolbutamide, and Lithium among others.*

FDA Label Image

Figure3:pharmacokineticsofvenlafaxineanditsmetaboliteo-desmethylvenlafaxine(odv)inspecialpopulations. (Image 03)

This document provides dosage recommendations for the medication Enlafaxine for patients with hepatic and renal impairments, as well as for patients undergoing hemodialysis. No dose adjustments are recommended for patients over 60 years of age or for males or females. The document also provides guidance for patients with the CYP2D6 polymorphism. The text appears to be a table outlining dosage adjustments for special populations.*

FDA Label Image

Structural Formula For Venlafaxine Hydrochloride (Image 04)

The text appears to be a chemical formula and product name. It includes the chemical symbols and names for various compounds and the product name "venlafaxine hydrochloride".*

FDA Label Image

Venlafaxine HCl Er 37.5mg Capsule 30 Count Blister Card (Image 05)

This is a prescription medication for Venlafaxine HCI ER 37.5mg capsules with a specific lot number and expiration date. The medication is produced by Teva Pharmaceuticals USA and is sold wholesale. The location of the pharmaceutical company is North Wales, PA, USA.*

FDA Label Image

Venlafaxine HCl Er 75mg Capsule 30 Count Blister Card (Image 06)

This is a description of a wholesale clinical solution for Venlafaxine HCI ER capsules. The package contains 30 capsules with a strength of 75mg. There is also a reference to a product called Mig, manufactured by Teva Pharmaceuticals USA Inc. However, the text is poorly recognized with errors and some other unclear references.*

FDA Label Image

Venlafaxine HCl Er 150mg Capsule 30 Count Blister Card (Image 07)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.